Improving outcomes in pediatric autoimmune liver disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Autoimmune Liver disease Network for Kids (A-LiNK) aims to enhance care for children with autoimmune liver diseases by establishing a shared clinical registry and a learning health network. This observational study focuses on collecting and sharing clinical data and treatment processes among participating institutions. By addressing the unique challenges of Pediatric Autoimmune Hepatitis and Primary Sclerosing Cholangitis, the study seeks to standardize monitoring and management practices, ultimately improving patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Clinical diagnosis of autoimmune hepatitis (AIH)
* Clinical diagnosis of primary sclerosing cholangitis (PSC)
* Clinical diagnosis of autoimmune sclerosing cholangitis (ASC)

Exclusion Criteria:

• History of liver transplant

Where it's running

• Stanford University
  Palo Alto, California, United States Recruiting
• Riley Children's Health
  Indianapolis, Indiana, United States Recruiting
• St. Louis Children's Hospital
  St Louis, Missouri, United States Recruiting
• Cincinnati Children's Hospital Medical Center
  Cincinnati, Ohio, United States Recruiting
• Nationwide Children's Hospital
  Columbus, Ohio, United States Recruiting
• UPMC Children's Hospital of Pittsburgh
  Pittsburgh, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Amy E Taylor, MD — Children's Hospital Medical Center, Cincinnati
• Study coordinator: Amy E Taylor, MD
• Email: amy.taylor@cchmc.org
• Phone: 513-636-4415

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Identifying liver disease-specific gut microbiomes

  This study is trying to find out if certain gut bacteria are linked to chronic liver diseases in adults, including autoimmune hepatitis and primary biliary cholangitis, by analyzing blood and stool samples from patients and their household members.

  Recruiting Chungnam National University Hospital · Daejeon, Jung-gu · NCT06519162

• Using Siplizumab to prevent immune issues in liver transplant patients with autoimmune liver disease

  This study is testing if a new medication called siplizumab can help prevent immune problems in adults with autoimmune liver disease who are getting a liver transplant.

  Recruiting Phase 1 Columbia University · New York, New York · NCT06455280

• Using MRI to predict outcomes in children with autoimmune liver disease

  This study is testing if MRI scans can help predict how well children with autoimmune liver diseases will do over time.

  Recruiting Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio · NCT03178630

• Using MRI to assess liver damage in children with autoimmune liver disease

  This study is testing if MRI scans can safely show liver damage in children with autoimmune liver diseases like PSC and AIH, helping doctors understand their condition better without needing invasive tests.

  Recruiting Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio · NCT03175471

• Inebilizumab for Autoimmune Hepatitis: a study in adults

  This trial tests whether inebilizumab can be safely used in adults with autoimmune hepatitis and whether it helps reduce liver disease activity and the need for steroids.

  Recruiting at 35 sites Phase 3 Amgen · Little Rock, Arkansas and 35 other locations · NCT07598825

• Elafibranor for adults with primary sclerosing cholangitis

  This trial will see if taking elafibranor once daily helps adults with primary sclerosing cholangitis compared with a placebo.

  Recruiting at 41 sites Phase 3 Ipsen · Chandler, Arizona and 230 other locations · NCT07387549

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.